RxDoctor Payments Data

Chikezie Amadi, MD

Interventional Cardiology · El Paso, TXNPI 1487616918

Payments from drug & device makers

$4,863in general payments, 2019–2025

Across 68 payments — averaging $71.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Bard Peripheral Vascular, Inc.$2K
  • Philips North America LLC$594
  • Abiomed$348
  • Edwards Lifesciences$240
  • Penumbra, Inc.$118
  • plus $334 from 10 others

What the payments were for

  • Travel & lodging$3,13064%
  • Food & beverage$1,73236%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,863 in reported general payments places this provider in the 25th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$29,560
Medicare patients
84
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$196,026
BrilintaTicagrelor69$67,550
XareltoRivaroxaban40$42,442
FarxigaDapagliflozin Propanediol42$41,168
EntrestoSacubitril/Valsartan14$14,557
Metoprolol Succinate294$2,984
ClopidogrelClopidogrel Bisulfate146$1,410
Nifedipine ErNifedipine62$995
Losartan Potassium145$950
Carvedilol151$891
Atorvastatin Calcium104$841
Hydralazine Hcl87$793
Metoprolol Tartrate94$596
Lisinopril78$549
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$196,026165 claims
NovartisEntresto$35$14,55714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →